Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

CLEVELAND–(BUSINESS WIRE)–$ATHX #ARS–Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute … [Read more…]

Fresenius Kabi, a Leader in Injectable Medicines, Introduces Data Matrix Barcodes on all Drugs as part of Companywide Commitment to Medication Safety

Initiative reduces manual data entry for clinicians and provides automatic identification and verification of products in medication management systems LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi–Fresenius Kabi announced today the introduction of a three-year plan to add GS1 Data Matrix barcodes to its pharmaceutical portfolio of vials, syringes, IV solutions and parenteral nutrition products at the unit of … [Read more…]

Voya selected as new service provider for Memorial Health System’s retirement plans

WINDSOR, Conn.–(BUSINESS WIRE)–Voya Financial, Inc. (NYSE: VOYA), announced today that it has been selected as the new recordkeeper and service provider for the Memorial Health System retirement savings plans. Memorial Health System, based in Gulfport, Mississippi, is a not-for-profit medical complex jointly owned by the City of Gulfport and Harrison County. Its mission is “to … [Read more…]

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch VIENNA, Va.–(BUSINESS WIRE)–$CVM #Multikine–CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over … [Read more…]

BTIG to Host Biotechnology Conference on August 8-9, 2022

NEW YORK–(BUSINESS WIRE)–BTIG announced today that it will hold its annual Biotechnology Conference on Monday, August 8th and Tuesday, August 9, 2022, in New York. The firm will host over 125 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include biotech policy … [Read more…]

Global Vaporizers Market Report 2022: Featuring Key Players Vicks, Vanker, GE Healthcare & Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Vaporizers Market Report 2022, by Type, by Application, by Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The global vaporizers market is expected to grow from $13.05 billion in 2021 to $17.15 billion in 2022 at a compound annual growth rate (CAGR) of 31.4%. The market is expected to reach $44.96 … [Read more…]

2022 V Foundation Wine Celebration Raises $6.5 Million

NAPA, Calif.–(BUSINESS WIRE)–#CancerResearch—The V Foundation for Cancer Research, a top-rated cancer research charity, announced the 2022 V Foundation Wine Celebration raised more than $6.5 million during a full weekend of events in the Napa Valley, with proceeds supporting early detection research. The 2022 Wine Celebration weekend was hosted by V Foundation Board Member and Duke … [Read more…]

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

Assay helps detect drug resistant strains of HIV-1 CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics. … [Read more…]

HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus platinum-based chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with disease progression following … [Read more…]

Rallybio Reports Second Quarter 2022 Financial Results

— Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets — — Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage … [Read more…]